DR info

Clinical trials : 112 / Drugs : 155 - (DrugBank : 55) / Drug target genes : 25 - Drug target pathways : 97

Lipodystrophy and other diseases between which drug repositioning (DR) might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Score (Drug repositionability)

ID	Diseases (Sorted by score)	Score
265	Lipodystrophy	-
46	Malignant rheumatoid arthritis	15.884
96	Crohn disease	14.463
299	Cystic fibrosis	13.500
97	Ulcerative colitis	13.159
13	Multiple sclerosis/Neuromyelitis optica	12.836
78	Hypopituitarism	12.084
2	Amyotrophic lateral sclerosis	10.419
6	Parkinson disease	10.370
236	Pseudohypoparathyroidism	8.144
63	Idiopathic thrombocytopenic purpura	6.205
21	Mitochondrial disease	6.139
246	Methylmalonic acidemia	5.068
65	Primary immunodeficiency	4.530
226	Interstitial cystitis with Hunners ulcer	3.943
84	Sarcoidosis	3.761
49	Systemic lupus erythematosus	3.580
8	Huntington disease	2.989
162	Pemphigoid	2.970
51	Scleroderma	2.854
271	Ankylosing spondylitis	2.758
50	Dermatomyositis	2.631
107	Juvenile idiopathic arthritis	2.573
93	Primary biliary cholangitis	2.176
77	Growth hormone secreting pituitary adenoma	2.000
268	Nakajo-Nishimura syndrome	2.000
325	Hereditary autoinflammatory syndrome	2.000
195	Noonan syndrome	2.000
263	Cerebrotendinous xanthomatosis	2.000
294	Congenital diaphragmatic hernia	1.938
81	Congenital adrenal hyperplasia	1.744
86	Pulmonary arterial hypertension	1.662
56	Behcet disease	1.522
67	Polycystic kidney disease	1.493
310	Congenital anomalies syndrome	1.385
94	Primary sclerosing cholangitis	1.328
113	Muscular dystrophy	1.304
75	Cushing disease	1.287
301	Macular dystrophy	1.231
225	Congenital nephrogenic diabetes insipidus	1.067
232	Carney complex	1.000
324	Methylglutaconic aciduria	1.000
191	Werner syndrome	1.000